In the latest trading session, Boston Scientific (BSX) closed at $42.6, marking a -1.46% move from the previous day.

Boston Scientific released the full $8 million holdback on schedule and with no claims Escrow release is the third funding catalyst Elutia has delivered in 2026, following the August closings of its Avenue Capital loan facility and SimpliDerm® divestiture The Company is now fully funded through the first year of the expected NXT-41x launch and into 2029 GAITHERSBURG, Md., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today announced it has received the full $8 million held in escrow in connection with the sale of its BioEnvelope business to Boston Scientific Corporation (NYSE: BSX).

BSX's MedSurg segment supports growth, with Endoscopy and Neuromodulation gains offsetting Urology challenges and portfolio gaps.

Shares of Boston Scientific Corporation (NYSE: BSX - Get Free Report) have been assigned an average rating of "Moderate Buy" from the thirty-one research firms that are covering the company, MarketBeat reports. Two analysts have rated the stock with a sell rating, six have assigned a hold rating and twenty-three have issued a buy rating on

Representative Kevin Hern (Republican-Oklahoma) recently sold shares of Boston Scientific Corporation (NYSE: BSX). In a filing disclosed on September 25th, the Representative disclosed that they had sold between $15,001 and $50,000 in Boston Scientific stock on August 31st. The trade occurred in the Representative's "HERN FAMILY FOUNDATION" account. Representative Kevin Hern also recently made the following

Boston Scientific stock slumped 55% over 12 months, driven by weakness in electrophysiology and WATCHMAN, which comprise only 26% of 2025 sales. Despite headline challenges, 74% of BSX's business grew at a robust 7% in Q2 2026, indicating underlying strength. Management cut 2026 guidance three times, with organic growth lowered to 5-6% and EPS guidance trimmed to $3.28-$3.32, amplifying investor pessimism.

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.

BSX's upcoming launches, from SEISMIQ 4CE to FARAFLEX, are likely to provide new growth opportunities across key businesses.

AGCO, AEG and BSX have been added to the Zacks Rank #5 (Strong Sell) List on September 21st, 2026.

Boston Scientific faces near-term pressure in electrophysiology, while Medtronic gains share and sees stronger momentum across key franchises.